Multiple System Atrophy Epidemiology Forecast 2025-2034

Multiple system atrophy (MSA) is a degenerative disease that manifests as a mix of parkinsonism, cerebellar dysfunction, and autonomic dysfunction. It is sporadic, progressive, and develops in adults (beyond 30 years of age). The incidence is 0.6-3 per 100,000 annually. 1.9 to 4.9 per 100,000 individuals is the prevalence.

Multiple System Atrophy Epidemiology Forecast Report Coverage

Expert Market Research's “Multiple System Atrophy Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of multiple system atrophy. It projects the future incidence and prevalence rates of multiple system atrophy cases across various populations. The study covers age, gender, and type as major determinants of the multiple system atrophy population. The report highlights patterns in the prevalence of multiple system atrophy over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on multiple system atrophy epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Multiple System Atrophy Understanding: Disease Overview

Multiple system atrophy (MSA) is an uncommon, progressive neurodegenerative disease condition, wherein the movement and the autonomic nervous system are impacted. In addition to issues with balance, coordination, bladder control, and blood pressure regulation, it is characterized by several symptoms that are comparable to those of Parkinson's disease, including tremors and rigidity. The progressive death of nerve cells in particular brain regions cause multiple system atrophy. Depending on the prevailing symptoms, there are two primary types, MSA-P (Parkinsonian) and MSA-C (Cerebellar). It usually affects adults in their 50s or 60s and gets worse over time, however the specific cause is unknown.

Multiple System Atrophy Epidemiology Perspective

The multiple system atrophy epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for multiple system atrophy epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for multiple system atrophy and their trends. The multiple system atrophy detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• With an estimated yearly incidence of 0.6-3 cases per 100,000 persons and a frequency of 1.9-4.9 cases per 100,000 people, multiple system atrophy (MSA) is an uncommon neurological condition.
• Geographical and ethnic regions have varying relative frequencies of motor subtypes. Mestizo, Japanese, and Korean individuals have higher rates of MSA-cerebellar (70%-80%). More MSA-parkinsonian people are found in North American and European populations (67%-84%).
• A study conducted in 2024 revealed that around 888 individuals reported that the mean age of MSA cases was 64 years old (range 38-91 year of age), with 53% of the patients being men and 47% being women.
• According to population-based research carried out in Europe, the prevalence of multiple system atrophy rose with age and ranged from 1.6 to 6.2 cases per 100,000 people. For the United States, the incidence estimates are currently available range from 0.6 to 0.8 cases per 100,000 person-years.

Age-Based Multiple System Atrophy Epidemiology Insights

Multiple system atrophy affects people over 30 years of age with a mean age of 55 to 60. With a typical life of 6-9 years, multiple system atrophy has a dismal prognosis and causes severe impairment due to its rapid progression. Some symptoms, such autonomic dysfunction, can be treated, but there is still a pressing need for disease modification.

Gender-Based Multiple System Atrophy Epidemiology Insights

A study conducted on prevalence of multiple system atrophy attributed that the condition frequently leads to symptoms like prostate enlargement. Hence, men over 60 should have their prostates examined. The estimated crude prevalence of multiple system atrophy is reported to be higher in men than in women (2.75 vs 1.19 per 100,000 persons), and varies from 0.52 to 17/100,000.

Country-wise Multiple System Atrophy Epidemiology Segment

The multiple system atrophy epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of multiple system atrophy varies between countries, owing to differences in factors such as genetic, environmental exposures, oxidative stress and other factors. The condition impacts 15,000 to 50,000 Americans, and people of all races may be affected. The crude prevalence of multiple system atrophy was 7.2 per 100,000 people, and it rose as people aged. In 2021, the age-adjusted prevalence, after being standardized to the US population, was 12.4 per 100,000.

Multiple System Atrophy: Treatment Overview

Multiple system atrophy (MSA) presently has no known cure. Instead, treatment aims to control symptoms and enhance quality of life. Levodopa is one medication that may help with mobility problems, but the effects are frequently mild. Certain medications, lifestyle modifications, and supportive therapies are used to treat autonomic symptoms such low blood pressure, urine issues, and sleep difficulties. Speech, occupational, and physical therapy are crucial for preserving independence and function. Because the condition is progressive and complex, a multidisciplinary approach to care is necessary.

Key Questions Answered

• What are the key findings of multiple system atrophy epidemiology in the 8 major markets?
• What will be the total number of patients with multiple system atrophy across the 8 major markets during the forecast period?
• What was the country-wise multiple system atrophy epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of multiple system atrophy patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of multiple system atrophy during the forecast period of 2025-2034?
• What are the currently available treatments in the multiple system atrophy market?
• What are the disease risks, signs, symptoms, and unmet needs of multiple system atrophy?

Scope of the Multiple System Atrophy Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of multiple system atrophy based on several factors.
• Multiple System Atrophy Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The multiple system atrophy report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.